Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • A-101: Phase II data

    Aclaris Therapeutics Inc., Malvern, Pa. Product: A-101 Business: Dermatology Molecular target: NA Description: Undisclosed topical treatment Indication: Treat seborrheic keratosis Endpoint: Physician lesion assessment …

    Published on 3/23/2015
  • Aducanumab: Interim Phase Ib data

    Biogen Idec Inc. (NASDAQ:BIIB), Cambridge, Mass. Neurimmune Holding AG, Schlieren, Switzerland Product: Aducanumab (BIIB037) Business: Neurology Molecular target: Beta amyloid Description: Human recombinant anti-beta …

    Published on 3/23/2015
  • ALLN-177: Phase IIa data

    Allena Pharmaceuticals Inc., Newton, Mass. Product: ALLN-177 Business: Endocrine/Metabolic Molecular target: NA Description: Oral recombinant oxalate degrading enzyme Indication: Treat hyperoxaluria and kidney stones …

    Published on 3/23/2015
  • ALZ-801: Phase I data

    Alzheon Inc., Lexington, Mass. Bellus Health Inc. (TSX:BLU), Laval, Quebec Product: ALZ-801 (formerly BLU8499) Business: Neurology Molecular target: Beta amyloid Description: Oral small molecule prodrug of tramiprosate,…

    Published on 3/23/2015
  • ASLAN002: Phase I data

    Aslan Pharmaceuticals Pte. Ltd., Singapore Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: ASLAN002, BMS-777607 Business: Cancer Molecular target: c-Met receptor tyrosine kinase; Macrophage stimulating 1 …

    Published on 3/23/2015
  • BAX 817: Phase III data

    Baxter International Inc. (NYSE:BAX), Deerfield, Ill. Product: BAX 817 Business: Hematology Molecular target: Factor VIIa Description: Recombinant Factor VIIa (rFVIIa) Indication: Treat hemophilia A or B Endpoint: …

    Published on 3/23/2015
  • BMS-663068: Additional Phase IIb data

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: BMS-663068 Business: Infectious Molecular target: HIV gp120 Description: HIV-1 attachment inhibitor that binds directly to HIV-1 gp120 Indication: Treat HIV-1…

    Published on 3/23/2015
  • BMS-955176: Phase IIa data

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: BMS-955176 Business: Infectious Molecular target: NA Description: Second generation HIV-1 maturation inhibitor Indication: Treat HIV-1 infection Endpoint: …

    Published on 3/23/2015
  • Brilinta: Additional Phase III data

    The Medicines Co. (NASDAQ:MDCO), Parsippany, N.J. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Brilinta ( Brilique-EU) ticagrelor (AZD6140) Business: Cardiovascular Molecular target: Purinergic receptor …

    Published on 3/23/2015
  • Bryostatin-1: Phase IIa final data

    Neurotrope Inc. (OTCQB:NTRP), Newark, N.J. Product: Bryostatin-1 Business: Neurology Molecular target: Protein kinase C (PKC) epsilon (PKCE) Description: Protein kinase C (PKC) epsilon (PKCE) activator Indication: Treat…

    Published on 3/23/2015
  • Cx611: Phase I data

    TiGenix N.V. (Euronext:TIG), Leuven, Belgium Product: Cx611 Business: Infectious Molecular target: NA Description: Suspension of expanded adipose-derived allogeneic stem cells Indication: Treat severe sepsis Endpoint: …

    Published on 3/23/2015
  • D-methadone: Phase I data

    Medeor Inc., New York, N.Y. Relmada Therapeutics Inc. (OTCQB:RLMD), New York, N.Y. Product: D-methadone Business: Neurology Molecular target: NMDA receptor Description: D optical isomer of racemic methadone, an NMDA …

    Published on 3/23/2015
  • ETC-1002: Additional Phase IIb data

    Esperion Therapeutics Inc. (NASDAQ:ESPR), Plymouth, Mich. Product: ETC-1002 Business: Endocrine/Metabolic Molecular target: AMP-activated protein kinase (AMPK); ATP citrate lyase (ACLY) Description: AMP-activated …

    Published on 3/23/2015
  • ETC-1002: Phase IIb data

    Esperion Therapeutics Inc. (NASDAQ:ESPR), Plymouth, Mich. Product: ETC-1002 Business: Endocrine/Metabolic Molecular target: AMP-activated protein kinase (AMPK); ATP citrate lyase (ACLY) Description: AMP-activated …

    Published on 3/23/2015
  • Etirinotecan pegol: Additional Phase III data

    Nektar Therapeutics (NASDAQ:NKTR), San Francisco, Calif. Product: Etirinotecan pegol (NKTR-102) Business: Cancer Molecular target: Topoisomerase I (TOP1) Description: Topoisomerase I (TOP1) inhibitor-polymer conjugate …

    Published on 3/23/2015
  • Evolocumab: Additional Phase III data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: Evolocumab (Repatha) (AMG 145) Business: Endocrine/Metabolic Molecular target: Proprotein convertase subtilisin/…

    Published on 3/23/2015
  • Imbruvica ibrutinib: Phase III data

    Pharmacyclics Inc. (NASDAQ:PCYC), Sunnyvale, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Imbruvica ibrutinib (PCI-32765) Business: Cancer Molecular target: Brutons tyrosine kinase (Btk) Description…

    Published on 3/23/2015
  • Lyxumia lixisenatide: Phase IIIb data

    Zealand Pharma A/S (CSE:ZEAL), Glostrup, Denmark Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Lyxumia lixisenatide (AVE0010, ZP10) Business: Endocrine/Metabolic Molecular target: Glucagon-like peptide-1 …

    Published on 3/23/2015
  • Masitinib: Phase Ib/II data

    AB Science S.A. (Euronext:AB), Paris, France Product: Masitinib (Masican) (AB1010) Business: Cancer Molecular target: Stem cell factor (SCF) receptor tyrosine kinase (c-Kit) (KIT) (CD117) Description: Stem cell factor (…

    Published on 3/23/2015
  • Praluent alirocumab: Additional Phase III data

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Praluent alirocumab (SAR236553, REGN727) Business: Endocrine/Metabolic Molecular target: Proprotein …

    Published on 3/23/2015
  • PRX002: Phase I data

    Prothena Corp. plc (NASDAQ:PRTA), Dublin, Ireland Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: PRX002 Business: Neurology Molecular target: Alpha synuclein (SNCA) Description: mAb targeting alpha synuclein…

    Published on 3/23/2015
  • PT003: Phase III data

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: PT003 Business: Pulmonary Molecular target: Adrenergic receptor beta 2 (ADRB2); Muscarinic receptor Description: Combination of glycopyrrolate (PT001), a long-…

    Published on 3/23/2015
  • Repatha evolocumab: Extension study data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: Repatha evolocumab (AMG 145) Business: Endocrine/Metabolic Molecular target: Proprotein convertase subtilisin/…

    Published on 3/23/2015
  • SIR-Spheres: Preliminary Phase III data

    Sirtex Medical Ltd. (ASX:SRX), Sydney, Australia Product: SIR-Spheres Business: Cancer Molecular target: NA Description: Yttrium-90 microspheres used for Selective Internal Radiation Therapy (SIRT) Indication: First-…

    Published on 3/23/2015
  • Uptravi selexipag: Additional Phase III data

    Actelion Ltd. (SIX:ATLN), Allschwil, Switzerland Nippon Shinyaku Co. Ltd. (Tokyo:4516), Kyoto, Japan Product: Uptravi selexipag (NS-304, ACT-293987) Business: Cardiovascular Molecular target: Prostacyclin (IP) receptor…

    Published on 3/23/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993